Belvarafenib clinical trials
Also written HM95573.
How each study uses belvarafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the belvarafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
| 2021 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Hanmi Pharmaceutical Company Limited (4) · Genentech, Inc. (1) · Hoffmann-La Roche (1) · Samsung Medical Center (1)
Often tested with
Tested in the same studies.
Cobimetinib (3) · Entrectinib (1) · Alectinib (1) · Atezolizumab (1) · Ipatasertib (1) · Ado-Trastuzumab Emtansine (1) · Inavolisib (1) · Pralsetinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test belvarafenib.
Studies
Open first, then newest update. How each study uses belvarafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid TumorsRecruitingPhase 2Samsung Medical CenterNCT07688356Written as Belvarafenib
- Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingPhase 2Hanmi Pharmaceutical Company LimitedNCT07449754Written as Belvarafenib
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingPhase 1Genentech, Inc.NCT04835805Written as Belvarafenib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Belvarafenib
- HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1Hanmi Pharmaceutical Company LimitedNCT03284502Written as HM95573, cobimetinib
- Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573CompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT02405065Written as HM95573
- Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid CancersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT03118817Written as HM95573
Codes
What other systems call belvarafenib · ClinicalTrials.gg INT002105
- UNII (FDA) 31M3WLJ3KGBELVARAFENIBOne source FDA
- NCI Thesaurus C121646BelvarafenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 31M3WLJ3KG | BELVARAFENIB | One source FDA |
| NCI Thesaurus | C121646 | Belvarafenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.